Association of circulating TNF-α and IL-6 with ageing and parkinsonism

Acta Neurologica Scandinavica

Volumn 100, Issue 1, 1999, Pages 34-41

  Dobbs, R J ^a,d   Charlett, A ^b   Purkiss, A G ^a   Dobbs, S M ^a   Weller, C ^a   Peterson, D W ^c  

^a HILLINGDON HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^d Research Group   (United Kingdom)

Author keywords

Aetiology; Ageing; Circulating TNF and IL 6; Cytokines; Environmental insult; Idiopathic parkinsonism; Inflammation immunity; Quantification of facets

Indexed keywords

CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; AGING; ARTICLE; BRADYKINESIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; HYPOKINESIA; IMMUNITY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; RIGIDITY; TREMOR;

EID: 0033005112     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1999.tb00721.x     Document Type: Article

References (71)

1. 1. Critchley M. The neurology of old age. Lancet 1931;i:1221-30.
2. 2. Barbeau A. Aging and the extrapyramidal system. J Am Geriatr Soc 1973;21:145-9.
3. 3. Kirollos C, O'Neill CJA, Dobbs RJ et al. Quantification of the cardinal signs of parkinsonism and of associated disability in spouses of sufferers. Age Ageing 1993;22:20-6.
4. 4. Charlett A, Dobbs RJ, Dobbs SM, Weller C, Brady P, Peterson DW. Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand 1999;99:26-35.
5. 5. Kurland LT. Epidemiology: incidence, geographic distribution and genetic considerations. In: Field WS, ed. Pathogenesis and treatment of parkinsonism. Springfield II.: Charles C Thomas, 1958;5-49.
6. 6. Koller WC. When does Parkinson's disease begin? Neurology 1992;42(Suppl. 4):27-31.
7. 7. Langston JW. MPTP as it relates to the etiology of Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW, eds. Etiology of Parkinson's disease, Neurological disease and therapy: 40. New York: Marcel Dekker Inc, 1995;387-99.
8. 8. Calne DB, Eisen A, McGreer E, Spencer P. Parkinson's disease, Alzheimer's disease and motorneurone disease: abiotrophic interaction between ageing and environment? Lancet 1986;ii:1067-70.
9. 9. Charlett A, Dobbs RJ, Purkiss AG et al. Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol Scand 1998;97:77-85.
10. 10. Rivier C. Role of Interleukins in the stress response. Methods Achieve Exp Pathol 1991;14:63-79.
11. 11. Watkins AD. Perceptions, emotions and immunity: an integrated homeostatic network. QJM 1995;88:283-94.
12. 12. Rothwell NJ, Hopkins SJ. Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci 1995;18:130-6.
13. 13. Rothwell NJ, Lueshi G, Toulmond S. Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. Pharmacol Ther 1996;69:85-95.
14. 14. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-9.
15. 15. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumour necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994;172:151-4.
16. 16. Mogi M, Harada M, Kondo T et al. Interleukin-1-beta, interleukin-6, epidermal growth-factor-alpha and transforming growth-factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994;180:147-50.
17. 17. Mogi M, Harada M, Narabayashi H, Ingaki H, Minami M, Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996;211:13-16.
18. 18. Lafortune L, Nalbantoglu J, Antel JP et al. Expression of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6) mRNA in adult human astrocytes: comparison with adult microglia and fetal astrocytes. J Neuropath Exp Neurol 1996;55:515-21.
19. 19. Poupard A, Emile J. Autoimmunity in Parkinson's disease. In: Hassler RG, Christ JF, eds. Adv Neurol 40. Parkinson-specific motor and mental disorders. Role of the pallidum: pathophysiological, biochemical and therapeutic aspects. New York: Raven Press, 1984;315-23.
20. 20. Dahlström A, Wigander D, Lundmark K, Gottfries C-G, Carvey PM, McRae A. Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. J Neural Transm (Suppl.) 1990;29:195-206.
21. 21. Fiszer U, Mix E, Fredrikson S, Kostulas V, Olsson T, Link H. γδ+ T cells are increased in patients with Parkinson's disease. J Neurol Sci 1994;121:39-45.
22. 22. Chiba S, Matsumoto H, Saitoh M, Kasahara M, Matsuya M, Kashiwagi M. A correlation study between serum adenosine-deaminase activities and peripheral lymphocyte subsets in Parkinson's disease. J Neurol Sci 1995;132:170-3.
23. 23. Fagiolo U, Cossarizza A, Scala E et al. Increased cytokine production in mononuclear cells of healthy old people. Eur J Immunol 1993;23:2375-8.
24. 24. Roubenoff R, Harris TB, Abad LW, Wilson PW, Dallal GE, Dinarello CA. Monocyte cytokine production in an elderly population; effect of age and inflammation. J Gerontol. Series A, Biol Sci & Med Sci 1998;53:M20-6.
25. 25. Mysliwska J, Bryl E, Foerster J, Mysliwski A. Increase of interleukin 6 and decrease of interleukin 2 production during the ageing process are influenced by the health status. Mech Ageing Development 1998;100:313-28.
26. 26. Ershler WB, Sun WH, Binkley N. The role of interleukin-6 in certain age-related diseases. Drugs Aging 1994;5:358-65.
27. 27. Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J. Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging 1994;15:771-2.
28. 28. Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol. Series A, Biol Sci & Med Sci 1997;52:M201-8.
29. 29. Hager K, Felicetti M, Seefried G, Platt D. Fibrinogen and aging. Aging 1994;6:133-8.
30. 30. De Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996;121:185-91.
31. 31. Mendall MA, Patel P, Asante M et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary artery disease. Heart 1997;78:273-7.
32. 32. Elneihoum AM, Falke P, Hedblad B, Lindgarde F, Ohlsson K. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997;131:79-84.
33. 33. Cimminiello C, Arpaia G, Toschi V et al. Plasma levels of tumour necrosis factor and endothelial response in patients with chronic arterial obstructive disease or Raynaud's phenomenon. Angiology 1994;12:1015-22.
34. 34. Wei J, Xu H, Davies H, Hemmings GP. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sciences 1992;51:1953-6.
35. 35. Ershler WB, Sun WH, Binkley N et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modified by dietary restriction. Lymphokine Cytokine Res 1993;12:225-30.
36. 36. McKane WR, Khosla S, Peterson JM, Egan K, Riggs BL. Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. J Bone Mineral Res 1994;9:1313-18.
37. 37. Bowes SG, Charlett A, Dobbs RJ et al. Gait in relation to ageing and idiopathic parkinsonism. Scand J Rehabil Med 1992;24:181-6.
38. 38. Charlett A, Weller C, Purkiss AG, Dobbs SM, Dobbs RJ. Breath of base whilst walking: effect of ageing and parkinsonism. Age Ageing 1998;27:27,49-54.
39. 39. Dobbs RJ, Bowes SG, Charlett A et al. Hypothesis: the bradyphrenia of Parkinsonism is a nosological entity. Acta Neurol Scand 1993;87:255-61.
40. 40. Quinn NP, Hussain FA. Parkinson's disease. Br Med J 1986;293:379-81.
41. 41. Quinn NP. Parkinsonism - recognition and differential diagnosis. Br Med J 1995;310:447-52.
42. 42. Pahwa R, Koller CK. Defining Parkinson's disease and Parkinsonism. In: Ellenberg JH et al., eds. Etiology of Parkinson's disease. Neurological disease and therapy 40, New York: Marcel Dekker Inc, 1995;1-54.
43. 43. Denham MJ, Jefferys P. Modified Tooting Bee Questionnaire. In: Source book of geriatric assessment. Vol 2. Hampshire: Karger, 1984;52.
44. 44. Medical Research Council. Memorandum No 45: Aids to the examination of the peripheral nervous system. London: Her Majesty's Stationary Office, 1975.
45. 45. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. In: Pichot T, ed. Psychological measurement in psychopharmacology 7. Modern problems in pharmacopsychiatry. Basel: Karger, 1974;151-9.
46. 46. Bowes SG, Dobbs RJ, Henley M et al. Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa. Eur J Clin Pharmacol 1992;43:483-9.
47. 47. Bowes SG, Clark PK, Charlett A et al. Objective outcome criteria in trials of antiparkinsonian therapy in the elderly: reliability, sensitivity and specificity of measures of brady- or hypokinesia. Br J Clin Pharmacol 1991;31:295-304.
48. 48. Wright BM. A simple mechanical ataxia-meter. J Physiol (Lond) 1971;218:27-28P.
49. 49. Southern RB, Rottman-Johnson B, Kanabrocki EL et al. Circadian characteristics of interleukin-6 in blood and urine of healthy men. In Vivo 1995;9:331-9.
50. 50. Royston JP. A simple method for evaluating the Shapiro-Francia W test of non-normality. Appl Stats 1993;32:297-300.
51. 51. Bartlett MS. Properties of sufficiency and statistical tests. Proc Roy Soc, Series A 1987;160:268-82.
52. 52. Belmin J, Bernard C, Corman B, Merval R, Esposito B, Tedgui A. Increased production of tumour necrosis factor and interleukin-6 by arterial wall of aged rats. Am J Physiol 1995;268:H2288-93.
53. 53. Fernandes G, Venkatraman JT, Turturro A, Attwood VG, Hart RW. Effect of food restriction on life span and immune function in long-lived Fisher-344×Brown Norway F1 rats. J Clin Immunol 1997;17:85-95.
54. 54. Spaulding CC, Walford RL, Effros RB. Calorie restriction inhibits age-related dysregulation of the cytokines TNF-alpha and IL-6 in C3B10RF1 mice. Mech Aging Dev 1997;93:87-94.
55. 55. Kim MJ, Aiken JM, Havighurst T, Hollander J, Ripple MO, Weindruch R. Adult-onset energy restriction of rhesus monkeys attenuates oxidative stress-induced cytokine expression by peripheral blood mononuclear cells. J Nutrition 1997;127:2293-301.
56. 56. Chelcuitte D, Mizuno S, Glowacki J. In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endocrinol Metab 1998;83:2043-51.
57. 57. Inserra P, Zhang Z, Ardestani SK et al. Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice. Proc Soc Exp Biol Med 1998;218:76-82.
58. 58. Dobbs RJ, Lubel DD, Charlett A et al. Hypothesis: age-associated changes in gait represent, in part, a tendency towards parkinsonism. Age Ageing 1992;21:221-5.
59. 59. Kirollos C, Charlett A, O'Neill CJA et al. Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism. Br J Clin Pharmacol 1996;41:557-64.
60. 60. Birkmayer W, Reiderer R. Parkinson's disease: biochemistry, clinical pathology and treatment. New York: Springer-Verlag, 1980;22-8.
61. 61. O'Neill CJA, Richardson MD, Charlett A et al. Could seborrhoeic dermatitis be implicated in the pathogenesis of parkinsonism? Acta Neurol Scand 1994;89:252-7.
62. 62. Purkiss AG, Charlett A, Wright DJ et al. Associations of immunoglobulins, IgG, IgA and IgM, with treatment in those with diagnosed parkinsonism, and with parkinsonian-like postural abnormality in those without. Br J Clin Pharmacol 1996;41:457-458P.
63. 63. Charlett A, Dobbs RJ, Weller C, Dobbs SM. Stasis in the gut: the source of xenobiotic in idiopathic parkinsonism. Eur J Clin Pharmacol 1997;52(Suppl):168.
64. 64. Singaram C, Ashraf W, Gaumnitz EA et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995;346:861-4.
65. 65. Kupsky WJ, Grimes MM, Sweeting J, Bectsch R, Cote LJ. Parkinson's disease and megacolon: hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987;37:1253-5.
66. 66. Edwards LL, Quigley EMM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992; 42:726-32.
67. 67. Dobbs SM, Charlett A, Dobbs RJ, Weller C. Does the protective effect of tobacco smoking in idiopathic parkinsonism reside in its laxative action. Naunyn Schmiedebergs Arch Pharmacol 1998;358(Suppl. 2): R479.
68. 68. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11-38.
69. 69. Kàlmàn JJA, Laird G, Dickens P et al. Serum interleukin-6 levels correlate with severity of dementia in Down's syndrome and Alzheimer's disease. Acta Neurol Scand 1997;96:236-40.
70. 70. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993;341:1251-4.
71. 71. Castenau PA, Garrett RS, Palinski W, Witztum JL, Campbell IL, Powell HC. Abnormal iron deposition associated with lipid peroxidation in transgenie mice expressing interleukin-6 in the brain. J Neuropath Exp Neurol 1998;57:268-82.